Latest On Protagonist Therapeutics, Inc (PTGX):
| Date/Time | Type | Description | Signal | Details |
|---|---|---|---|---|
| 2023-05-26 01:04 EST | News | Protagonist Therapeutics Sees Steady If Bumpy Progress | N/A |  |
| 2023-05-24 20:54 EST | News | Protagonist Therapeutics: All Quiet Heading Into An Important H2 2023 | N/A | |
| 2023-05-12 13:28 EST | News | Protagonist Therapeutics and Janssen's collaboration shows promise for oral therapy for IL-23-mediated diseases | N/A | |
| 2023-05-05 17:50 EST | News | Protagonist GAAP EPS of -$0.67 in-line | N/A | |
| 2023-04-05 11:14 EST | News | Protagonist Therapeutics prices $100M offering | N/A | |
About Protagonist Therapeutics, Inc (PTGX):
Protagonist Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address unmet medical needs. It is developing PTG-300, an injectable hepcidin mimetic that is in Phase II clinical trial for the treatment of patients with polycythemia vera and hereditary hemochromatosis, as well as for the treatment of other blood disorders; PTG-200, an oral, interleukin-23 receptor specific antagonist peptide, which is in phase II clinical trial for the treatment of moderate-to-severe Crohn's disease; and PN-943, an oral, alpha-4-beta-7 specific integrin antagonist that is in Phase II clinical trial for treating inflammatory bowel disease (IBD). The company has a license and collaboration agreement with Janssen Biotech, Inc. for the devel read more...opment, manufacture, and commercialization of PTG-200 for the treatment of Crohn's disease and ulcerative colitis; and PN-235 and PN-232 oral interleukin-23 receptor antagonist candidates for IBD and non-IBD indications. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.
General
- Name Protagonist Therapeutics, Inc
- Symbol PTGX
- Type Common Stock
- Exchange NASDAQ
- Currency USD
- Country USA
- SectorHealthcare
- IndustryBiotechnology
- Full Time Employees 79
- Fiscal Year EndDecember
- IPO Date2016-08-11
- Gic SectorHealth Care
- Gic GroupPharmaceuticals, Biotechnology & Life Sciences
- Gic IndustryBiotechnology
- Gic SubIndustryBiotechnology
- Web URLhttp://www.protagonist-inc.com
Valuation
- Price/Sales (Trailing 12 Mt.) 37.31
- Price/Book (Most Recent Quarter) 4.86
- Enterprise Value Revenue 37.04
Financials
- Most Recent Quarter 2020-12-31
- Current Year EPS Estimate -$1.97
- Next Year EPS Estimate -$2.12
- Next Quarter EPS Estimate -$0.54
- Profit Margin -231%
- Operating Margin -225%
- Return on Assets -17%
- Return on Equity -37%
- Revenue 28.63 million
- Earnings Per Share -$2.74
- Revenue Per Share $0.83
- Gross Profit 28.63 million
- Quarterly Earnings Growth 107.8%
Highlights
- Market Capitalization 1.36 billion
- EBITDA -70271000
- Analyst Target Price $37
- Book Value Per Share $6.39
Share Statistics
- Shares Outstanding 43.81 million
- Shares Float 27.88 million
- % Held by Insiders 161%
- % Held by Institutions 93.65%
- Shares Short 2.77 million
- Shares Short Prior Month 2.78 million
- Short Ratio 8.34
- Short % of Float 7%
- Short % of Shares Outstanding 6%
Technicals
- Beta 1.55
- 52 Week High $31.58
- 52 Week Low $5.44
- 50 Day Moving Average 26.03
- 200 Day Moving Average 22.63
Dividends
- Dividend Date N/A
- ExDividend Date N/A
- Dividend Yield 0%
Protagonist Therapeutics, Inc (PTGX) Dividend Calendar:
Protagonist Therapeutics, Inc (PTGX) Earnings History:
Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.
Protagonist Therapeutics, Inc (PTGX) Company Financial Statements:
Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.
Income Statement:
| Date |
|---|
| Research Development |
| Income Before Tax |
| Selling General Administrative |
| Gross Profit |
| Ebit |
| Operating Income |
| Income Tax Expense |
| Total Revenue |
| Cost of Revenue |
| Total Other Income Expense Net |
| Net Income From Continuing Operations |
| Net Income Applicable to Common Shares |
Cash Flow:
| Date |
|---|
| Investments |
| Change to Liabilities |
| Total Cash Flow from Investing Activities |
| Net Borrowings |
| Total Cash Flow from Financial Activities |
| Change to Operating Activities |
| Change in Cash |
| Total Cash from Operating Activities |
| Depreciation |
| Other Cash Flow from Investing Activities |
| Change to Inventory |
| Change to Account Receivables |
| Other Cash Flow from Financing Activities |
| Change to Net Income |
| Capital Expenditures |
Balance Sheet:
| Date |
|---|
| Total Liabailities |
| Total Stockholder Equity |
| Other Current Liabilities |
| Total Assets |
| Common Stock |
| Other Current Assets |
| Retained Earnings |
| Other Liabilities |
| Other Assets |
| Cash |
| Total Current Liabilities |
| Other Stockholder Equity |
| Property, Plant & Equipment |
| Total Current Assets |
| Long Term Investments |
| Net Tangible Assets |
| Short Term Investments |
| Long Term Debt |
| Inventory |
| Accounts Payable |
Protagonist Therapeutics, Inc (PTGX) Chart:
Protagonist Therapeutics, Inc (PTGX) News:
Below you will find a list of latest news for Protagonist Therapeutics, Inc (PTGX) from major news sources. You can filter the results to only show news from a specific source.
No recent news available
Protagonist Therapeutics, Inc (PTGX) Options:
A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.
Latest PTGX Trades:
Protagonist Therapeutics, Inc (PTGX) SEC Filings:
An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.
| Date | Form Type | View |
|---|---|---|
| 2020-11-04 | 8-K (Current report) | |
| 2020-11-04 | 10-Q (Quarterly report [Sections 13 or 15(d)]) | |
| 2020-10-02 | 8-K/A (Current report) | |
| 2020-09-11 | 8-K (Current report) | |
| 2020-08-18 | 3 (Initial statement of beneficial ownership of securities) | |
| 2020-08-18 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-08-13 | 8-K (Current report) | |
| 2020-08-12 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-08-06 | 8-K (Current report) | |
| 2020-08-06 | 10-Q (Quarterly report [Sections 13 or 15(d)]) | |
| 2020-06-09 | SC 13G/A (Statement of acquisition of beneficial ownership by individuals) | |
| 2020-06-09 | SC 13G/A (Statement of acquisition of beneficial ownership by individuals) | |
| 2020-06-08 | SC 13D/A (General statement of acquisition of beneficial ownership) | |
| 2020-05-29 | 8-K (Current report) | |
| 2020-05-29 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-05-29 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-05-29 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-05-29 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-05-29 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-05-29 | 4 (Statement of changes in beneficial ownership of securities) | |
Protagonist Therapeutics, Inc (PTGX) Insider Transactions:
Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Protagonist Therapeutics, Inc (PTGX). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 161%
Institutional Ownership: 9365%
| Transaction Date | Insider Name | Insider Title | Type | Shares Number | Shares Price | Total Transaction | Shares Held After Transaction | Link |
|---|---|---|---|---|---|---|---|---|
| 2020-08-11 | CHAITAN PHD KHOSLA | Director | Sell | 2,499.00 | 17.19 | 42,952.06 | 0.00 | |
| 2020-08-11 | CHAITAN PHD KHOSLA | Director | Buy | 2,499.00 | 1.89 | 4,723.11 | 2,499.00 | |
| 2020-03-20 | DINESH V PH D PATEL | President and CEO | Buy | 10,000.00 | 1.89 | 18,900.00 | 439,990.00 | |
| 2020-03-12 | HAROLD E SELICK | Director | Buy | 12,000.00 | 6.70 | 80,400.00 | 15,310.00 | |
| 2020-03-12 | DINESH V PH D PATEL | President and CEO | Buy | 18,344.00 | 1.16 | 21,279.04 | 429,990.00 | |
| 2019-12-03 | Donald A. Kalkofen | Chief Financial Officer | Buy | 562.00 | 5.09 | 2,860.58 | 1,175.00 | |
| 2019-12-03 | DINESH V PH D PATEL | President and CEO | Buy | 10,000.00 | 5.55 | 55,500.00 | 389,824.00 | |
| 2019-12-03 | DINESH V PH D PATEL | President and CEO | Buy | 20,000.00 | 5.65 | 113,000.00 | 409,824.00 | |
| 2019-12-03 | Suneel Gupta | EVP Clinical Operations | Buy | 30,000.00 | 5.13 | 153,900.00 | 49,500.00 | |
| 2019-12-03 | Donald A. Kalkofen | Chief Financial Officer | Buy | 613.00 | 5.10 | 3,126.30 | 613.00 | |
| 2019-12-03 | Bryan Giraudo | Director | Buy | 8,000.00 | 5.70 | 45,620.00 | 8,000.00 | |
| 2019-11-26 | DINESH V PH D PATEL | President and CEO | Buy | 4,000.00 | 1.16 | 4,640.00 | 379,824.00 | |
| 2019-08-06 | DINESH V PH D PATEL | President and CEO | Sell | 10,792.00 | 8.85 | 95,535.10 | 374,792.00 | |
| 2019-08-06 | David Y Liu | Chief Scientific Officer | Sell | 3,395.00 | 8.85 | 30,044.05 | 49,802.00 | |
| 2019-04-01 | HAROLD E SELICK | Director | Buy | 3,310.00 | 1.31 | 4,336.10 | 3,310.00 | |
| 2019-03-01 | Richard S. Shames | Chief Medical Officer | Sell | 657.00 | 8.03 | 5,275.71 | 32,021.00 | |
| 2019-03-01 | DINESH V PH D PATEL | President and CEO | Sell | 2,183.00 | 8.03 | 17,529.49 | 383,831.00 | |
| 2019-03-01 | David Y Liu | Chief Scientific Officer | Sell | 810.00 | 8.03 | 6,504.30 | 51,197.00 | |
| 2019-02-28 | Suneel Gupta | EVP Clinical Operations | Buy | 7,500.00 | 17,500.00 | | ||
| 2019-02-28 | Samuel R Saks | Chief Development Officer | Buy | 2,500.00 | 2,500.00 | |